

Prescribing and Formulary Panel

Minutes of the meeting held on November 2nd 2021 at the Oak MDT Room

Present

Geraldine O’Riordan, Prescribing Advisor and Chair (GOR)

Beverley Hall, Chief Pharmacist (BH)

Tom Saunders, Medical Specialist Group (HD)

Hong Choo, Lead MI Pharmacist representing the PEH Pharmacy Manager, HSC (HC)

Douglas Wilson, Queens Road Medical Practice (DW)

Peter Gomes, Medical Specialist Group (PG)

Apologies

Nikki Brink, States-Employed Doctors and DPH (NB)

Paul Williams, Island Health (PH)

Hamish Duncan, Medical Specialist Group (HD),

Mike McCarthy, Healthcare Group (MMC)

1: Minutes

The draft minutes of the October 2021 meeting were approved.

2. New Drugs

The following products were considered

1. Lurasidone

This product was requested for a Guernsey patient whose treatment with virtually all other atypical antipsychotics had been unsuccessful. There was a discussion about the probability of a new agent being effective and tolerated when ten or more had not. It was noted that it is considered “red” in many NHS formularies and that there was a relative absence of evidence of superiority over other agents. The cost is significantly higher than the other oral atypicals, all of which are available generically. With regret it was agreed to decline this request.

Action : GOR

2. Ronapreve

This product, an in-hospital treatment for people with COVID-19, has received a conditional marketing authorisation in the UK. It is being requested for off-label use by the Medical Cell. The product's approval as per the paper.

Action: GOR

3. New NICE TA drugs

Nine new TAs now ready for implementation were noted.

Actions GOR

4. Cost-neutral /minor amendments

The following products were considered and recommended

Venlafaxine 37.5 mg per 5 ml oral suspension	Costs £47.62 for 100mls special. Requested for patient coming off venlafaxine who is encountering severe withdrawal effects with the lowest strength tablet.
Imiquinod 3.75% Cream in addition to Imiquinod 5% Cream which is already available	3.75% cream costs £54.76 for 28 sachets vs £48.60 for 12 sachets of the 5%. Requested for patients for whom 5% strength causes severe reactions.

5. Private Chemotherapy requests

A request for Avelumab and Axitinib (oral and already in use) for advanced/metastatic renal carcinoma for a private patient with extensive lung metastases was approved.

6. Anti-VEGF Drugs Policy Update

Version 2 was approved as per the paper, subject to some minor amendments and new formatting.

7. AOB none

8: Date of next meeting: Tuesday December 7th 2021 either via TEAMS or at the Oak MDT Room